Contact
Subscribe
Knowledge Hub
Modalities
Topics & Trends
CDMO Pricing
State of the Industry
Research
Pharma’s Almanac
Mobile Navigation
Subscribe for the Newsletter
Loading…
Loading…
Knowledge Hub
Filter
Filter
Sort By
Newest First
Modalities
Topics
Reset
Mobile Filter Sidebar
1 / 3
Development CDMO
The Case for Earlier CDMO Involvement in Drug Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-09-26-PA-02
Sep 2, 2026
MPS
What Will It Take for Organ-on-Chip Data to Replace Animal Studies?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-18
Aug 31, 2026
small molecules
Small Molecule Discovery and Development Trends
David Alvaro, Ph.D.
Pharma's Almanac
NI-8-26-MA50
Aug 28, 2026
Chinese Biopharma
Pharmaceutical Innovation in China Takes Center Stage
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-17
Aug 25, 2026
Potency Assurance
Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-16
Aug 24, 2026
Preparedness
Preparing Manufacturing Networks for the Next Pandemic
Pharma's Almanac
PAO-08-26-PA-14
Aug 20, 2026
Prevention
Preventive Therapeutics Beyond Vaccines
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-13
Aug 18, 2026
Mucosal Vaccine
Mucosal Vaccination and the Quest for Better Immunity
David Alvaro, Ph.D.
Pharma's Almanac
PAO-08-26-PA-12
Aug 17, 2026
Vaccine Development
New Vaccine Technologies Expand the Frontiers of Prevention and Treatment
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-11
Aug 14, 2026
LAIs
Seven Biotechs Developing Long-Acting Injectable Drugs
Vedangi Joshi
Nice Insight
PAO-08-26-PA-10
Aug 10, 2026
In Vivo CAR-T
Five Companies Bringing In Vivo CAR-T Therapy Closer to the Clinic
Emma Gormlie
Nice Insight
PAO-07-26-PA-13
Jul 30, 2026
Combination Products
Collaboration is Key to Successful Injectable Drug–Device Combination Product Development
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-08-26-PA-05
Jul 27, 2026
Stem Cells
Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-07-26-PA-11
Jul 22, 2026
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19
Jul 20, 2026
Rare Cancer CGT
Developing Cell and Gene Therapies for Rare Oncology Applications
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-10
Jul 16, 2026
Drug Delivery
Intracellular Delivery: Reaching Targets Beyond the Cell Surface
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-07
Jul 14, 2026
Tumor-Agnostic
Moving Beyond Tumor Origin: The Rise of Tissue-Agnostic Oncology
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-26-PA-05
Jul 8, 2026
Next-Gen Delivery
Beyond Lipid Nanoparticles: The Search for Next-Generation Delivery Platforms
Pharma's Almanac
PAO-07-26-PA-06
Jul 6, 2026
Protein Conformation
Designing Drugs Against Moving Proteins: Drug Discovery Enters the Era of Protein Conformational Ensembles
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-17
Jul 6, 2026
LAIs
The Long View: How Extended-Duration Therapies Are Reshaping Patient Care
Pharma's Almanac
PAO-07-26-PA-01
Jul 1, 2026
1 / 3